Hester Biosciences Ltd.
Snapshot View

2393.05 -26.50 ▼-1.1%

03 August 2021, 04:00:00 P.M.
Volume: 564

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.hester.in
Financial Indicators
Market Cap 2,058.28 Cr.
Earnings per share (EPS) 40.47 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 59.78 Trailing Twelve Months Ending 2021-03
Industry PE 32.66 Trailing Twelve Months Ending 2021-03
Book Value / Share 268.38 Trailing Twelve Months Ending 2021-03
Price to Book Value 9.02 Calculated using Price: 2,419.55
Dividend Yield 0.41 Period Ending 2021-03
No. of Shares Subscribed 0.85 Cr. 8,506,865 Shares
FaceValue 10
Company Profile

Hester Biosciences was incorporated on April 29, 1987 as a Private Limited Company by the name of Hester Pharmaceuticals Limited. It was subsequently converted into a Public Limited Company on November 1, 1993. The company is engaged in the manufacturing of poultry vaccines. The company has been promoted by Rajiv D. Gandhi his brother Sanjiv D. Gandhi and Dr. Bhupendra V. Gandhi. The company changed its name to the present in 2008.

The company is a 100% biotech company producing animal biologicals. Located near the city of Ahmedabad, in the state of Gujarat, in Western India, Hester has a state-of-the-art facility to produce live and killed (Inactivated) veterinary vaccines.

Production procedures for poultry vaccines based on in-house advanced capabilities are being followed in the areas of virus propagation in specific pathogen-free embryos, tissue culture, batch fermentation of bacteria, lyophilisation and emulsion preparation.

Hester on December 22, 2008 launched a poultry vaccine against Coryza disease in chicken, containing 3 serotypes – A, B & C.

Hester is the first company in India to manufacture the Coryza vaccine with 3 strains as against other companies manufacturing the vaccine with only 2 serotypes - A & C. Coryza disease is of economical importance to poultry farmers as it causes a drop in egg production in laying birds.

Hester currently manufactures 39 types of poultry vaccines against various poultry diseases.

Product range of the company includes:

  • Live Vaccines
  • Killed Vaccines
  • Diagnostic kits &  Seromonitoring services

Achievements/ recognition:

  • GMP and ISO 9001:2000 certified company

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-1.10%
1 Week
+1.85%
1 Month
-7.33%
3 Month
+8.86%
6 Month
+40.20%
1 Year
+77.48%
2 Year
+56.35%
5 Year
+230.60%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 14.28 12.88 16.73 20.56 20.38 17.57 25.59 16.38 16.16
Return on Capital Employed (%) 20.10 17.78 17.26 18.98 19.75 20.20 26.64 16.53 17.33
Return on Assets (%) 8.28 6.89 8.84 11.08 11.43 10.10 14.97 9.04 8.70

Balance Sheet View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 67 75 85 102 122 141 177 201 228
Non Curr. Liab. 16 20 38 41 48 44 70 97 114
Curr. Liab. 39 45 35 38 38 55 49 83 61
Minority Int. 1 1 3 5 5 4 4 5 8
Equity & Liab. 124 142 160 186 213 244 299 387 411
Non Curr. Assets 74 85 100 112 133 146 158 227 250
Curr. Assets 50 57 60 74 80 98 142 159 162
Misc. Exp. not W/O
Total Assets 124 142 160 186 213 244 299 387 411

Profit Loss View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 65 69 90 101 123 136 178 183 214
Other Income 0 1 0 1 0 3 7 6 5
Total Income 65 70 90 102 124 138 185 190 219
Total Expenditure -43 -45 -65 -68 -82 -89 -110 -128 -146
PBIDT 22 25 26 34 41 50 75 62 73
Interest -3 -6 -5 -4 -4 -4 -7 -7 -7
Depreciation -4 -5 -6 -6 -7 -10 -12 -13 -13
Taxation -5 -4 -5 -6 -8 -13 -16 -10 -15
Exceptional Items 3 -3
PAT 9 9 13 19 23 23 41 31 35

Cash Flow View Details

Particulars 9 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 12 9 20 19 35 38 47 37 58
Cash Fr. Inv. -23 -15 -21 -13 -30 -26 -22 -74 -38
Cash Fr. Finan. 10 7 7 -7 2 -11 3 19 -18
Net Change -1 2 5 -1 6 1 28 -19 1
Cash & Cash Eqvt 2 4 6 5 11 12 41 24 21

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 54.09 53.74 53.73 53.73 53.73 53.73 53.73 53.73 53.73
Public 45.91 46.26 46.27 46.27 46.27 46.27 46.27 46.27 46.27
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 03 Aug 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Details of Loss of Certificate
Sat, 24 Jul 2021
Fixes Book Closure for Final Dividend & AGM (Cut-off date for e-voting)
Hester Biosciences Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from August 07 2021 to August 17 2021 (both days inclusive) for the purpose of Payment of Final Dividend & 34th Annual General Meeting (AGM) of the Company to be held on August 17 2021.
Sat, 24 Jul 2021
Corporate Action - Book Closure For Dividend
The Register of Members and Share Transfer Books of the Company will remain closed from Saturday 7 August 2021 to Tuesday 17 August 2021 (both days inclusive) for the purpose of determining shareholders entitlement for final dividend as recommended by the Board of Directors at their meeting held on Tuesday 8 June 2021 on the equity shares at the rate of 100% (i.e. INR 10 per share) for the financial year 2020-21 subject to approval of members at the ensuing annual general meeting.

Technical Scans View Details

Mon, 02 Aug 2021
Higher Delivery Quantity Higher Delivery Quantity
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below
William %R Bullish William %R Bullish
Fri, 30 Jul 2021
Close Crossing Last Week Low Close Crossing Last Week Low
S Close Below Last Week Low

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,816.50 794.85 +2.6%
Divi's Laboratories Ltd. 130,822.92 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. 78,219.21 4,721.20 +0.4%
Cipla Ltd. 74,356.30 927.25 +0.6%
Cadila Healthcare Ltd. 60,574.85 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. 58,218.41 4,076.05 +0.7%
Piramal Enterprises Ltd. 56,317.82 2,507.65 +0.7%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 30.95 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 65.93 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.02 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 30.92 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.39 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 387.19 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 42.27 2,507.65 +0.7%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.88 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2021-03 14.08 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.37 4,721.20 +0.4%
Cipla Ltd. Consolidated 2021-03 4.06 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.66 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.67 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.65 2,507.65 +0.7%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 0.18 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 10.09 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,507.65 +0.7%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 12.53 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,507.65 +0.7%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 17,131.99 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,507.65 +0.7%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 794.85 +2.6%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,990.05 +1.3%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,721.20 +0.4%
Cipla Ltd. Consolidated 2020-03 1,546.98 927.25 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 592.10 +0.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,076.05 +0.7%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,507.65 +0.7%